Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading ...

Regeneron’s trial shows semaglutide combos improve fat loss while preserving muscle in obesity treatment. Read more here.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

FDA FLAGS SEVERE ITCH — Patients who stop using the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) may ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...